Supplementary Materialsja9b11709_si_001. the CCH 18F-trifluoromethylation of model peptides made up of L-tryptophan and/or L-tyrosine residues using [18F]CF3Thus2NH4 and = 2) after semipreparative HPLC (= 3, Am = 0.28 0.08 GBq/mol) after purification by HPLC. The full total synthesis period from [18F]fluoride to octreotide[Trp(2-CF218F)] was 133 min. This computerized protocol allowed an in vivo Family pet imaging test out this [18F]CF3-peptide on na?ve SpragueCDawley rats, an initial research suggesting excretion via the gastrointestinal pathway as well as the kidneys.32,49?51 To conclude, we’ve reported the initial protocol allowing direct 18F labeling of unmodified peptides at tryptophan and tyrosine residues (with high selectivity for tryptophan) via direct CCH 18F-trifluoromethylation. This technique is a fresh tool to speed up the breakthrough of 18F-peptides as imaging agencies aswell as the introduction of peptide-based medications. The book was needed with the technique 18F reagent [18F]CF3SO2NH4, which was ready in a single stage from [18F]fluoride, a difluorocarbene reagent, and a way to obtain SO2. The iron sodium was necessary to overcome the down Canagliflozin hemihydrate sides due to [18F]CF3SO2NH4 getting the restricting reagent, allowing CCH 18F-trifluoromethylation of peptides as complex as insulin thereby. The computerized radiosynthesis of octreotide[Trp(2-CF218F)] from [18F]fluoride allowed in vivo Family pet imaging. This main milestone, unrivaled by known strategies utilizing size tagged prosthetics minimally,23,52,53 pieces the stage for in-depth investigations of relevant Canagliflozin hemihydrate peptides clinically. Because of the real variety of reactions counting on Langlois-type reagents, [18F]CF3SO2NH4 could broaden significantly the radiochemical space for PET applications beyond the peptides explained herein. Acknowledgments Financial support was provided by the Agency for Technology, Technology and Study (A*Celebrity, Singapore, to Canagliflozin hemihydrate C.W.K.), the BBSRC (BB/M016757/1 and BB/P026311/1), European Union Horizon 2020 Marie Sk?odowska-Curie Give Agreement 675071 (to M.I.), the Swiss National Science Basis (P2BSP2_178609 to P.G.I.), CRUK (C5255/A16466), the Medical Study Council (MR/R01695X/1), and the EPSRC (EP/L025604/1, NS/A000024/1, and EP/L015838/1). The authors say thanks to Dr. M. Tredwell for helpful discussions. Supporting Info Available The Assisting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.9b11709. Detailed experimental methods, characterization of fresh compounds, automation protocol, and in vivo experiments (PDF) Author Present Address C.W.K: Institute of Chemical and Executive Sciences, A*Celebrity, 1 Pesek Road, Jurong Island, 627833 Singapore. Author Contributions # C.W.K. and O.T. Vwf contributed equally. Notes The authors declare no competing financial interest. Supplementary Material ja9b11709_si_001.pdf(20M, pdf).